Excluding partnership monies, biotechs raised $13.2 billion in Q1, the first time since Q1 in 2000, during the genomics bubble, when the industry raised >$13 billion. Deals by Gilead Pharmaceuticals (Foster City, California) as well as specialty pharmas pushed debt financings up to $9.5 billion, nearly five times the amount raised in Q1 last year. Follow-on offerings were also up 33%, but venture money and initial public offerings lagged.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yang, W. Q1 strong out of the gates. Nat Biotechnol 29, 382 (2011). https://doi.org/10.1038/nbt.1870
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.1870
